To read a merger announcement, focus on four items: the premium over the target's recent share price, the form of payment, the conditions that must be met, and the timeline with its deadlines and break fees. Boston Scientific's (BSX) 2026 agreement to buy Penumbra (PEN) for $374 per share, about $14.5 billion, shows why each matters [1][2]. The headline price stayed fixed, but a 53% fall in Boston Scientific's stock cut the value of the stock portion, and as of September 25, 2026 Penumbra traded at $318.89, close to the blended value of about $319 per share [1][5].
How to read a merger announcement: the four parts
- Premium: how much more the buyer pays than the market price before the news.
- Consideration: cash, stock or both, and whether holders can choose.
- Conditions: shareholder votes, antitrust reviews and other approvals.
- Timeline and protections: expected closing date, outside date and termination fees.
Merger documents repeat these items in a standard order: the press release gives the summary, and the proxy statement or prospectus sent to shareholders gives the details [1].
Step 1: Measure the premium
Boston Scientific announced the deal on January 15, 2026 [2]. According to the proxy statement/prospectus, the $374 price represented a 19% premium to Penumbra's 30-day volume-weighted average price, a 30% premium to its 90-day average and a 15% premium to its 52-week high, all measured through January 13, 2026 [1]. Penumbra closed at $313.43 on January 14, the day before the announcement, so the premium to the last close was about 19% [5].
A good habit is to check several premium measures. A one-day premium can look small if the stock rose on rumors, and a 52-week-high premium shows whether long-term holders are being paid more than the stock's recent peak. The same document also gives valuation multiples: about 10.2 times Penumbra's 2025 revenue and about 68.8 times its 2025 Adjusted EBITDA [1]. Those are high multiples, typical for a fast-growing medical device company rather than a mature business. DataPorium's deal record shows the same picture, with enterprise value of about 10.2 times sales [4].
Step 2: Understand the consideration
The form of payment decides how much risk the seller keeps. Each Penumbra holder could elect either $374.00 in cash or 3.8721 Boston Scientific shares per Penumbra share [1]. The stock ratio was set so that both options were worth $374 using Boston Scientific's 10-day average price of $96.59 before the announcement [1]. But these choices are subject to proration: in total, 73.26% of Penumbra shares will receive cash and 26.74% will receive stock, whatever holders choose [1].
Why the value changed after signing
The cash part is fixed; the stock part moves with the buyer's share price. Boston Scientific stock fell from $93.74 on January 14 to $43.92 on September 25, 2026 [5]. At that price, the 3.8721-share option was worth about $170, and the blended value per Penumbra share was about $319:
| Component | Share of Penumbra stock | Value per share (Sep 25) | Weighted value |
|---|---|---|---|
| Cash option | 73.26% | $374.00 | $273.99 |
| Stock option (3.8721 BSX) | 26.74% | about $170.06 | about $45.47 |
| Blended value | 100% | about $319.46 |
Penumbra's closing price of $318.89 on September 25 sat just below that blended value [5]. The lesson for readers: a fixed exchange ratio moves value risk to the seller's shareholders, and a proration clause means holders may not receive the form of payment they elect.
Step 3: Check the conditions
Most deals need three kinds of approval. First, the target's shareholders: Penumbra holders approved the merger on May 6, 2026, with 28,564,786 votes for and 85,334 against [3]. Second, antitrust clearance: under the Hart-Scott-Rodino Act, the companies filed with US regulators, and on March 16, 2026 both received a Second Request from the Federal Trade Commission, a demand for more information that extends the review [2]. Third, other customary conditions, such as no court order blocking the deal [1]. A Second Request is common for large deals between competitors and does not mean the deal will be blocked, but it adds months to the timeline.
Step 4: Read the timeline and the break fees
As of its second-quarter report, Boston Scientific expected to complete the deal in the second half of 2026 [2]. The merger agreement sets an initial outside date of January 14, 2027, after which either side may walk away under defined conditions [1]. Termination fees show how each party shares the risk [1]:
- Penumbra pays Boston Scientific $525 million if it accepts a better offer or in certain other cases.
- Boston Scientific pays Penumbra $900 million if the deal fails because the outside date passes or a final court or regulatory order blocks it.
The larger reverse fee, about 6% of the $14.5 billion value, signals that the buyer accepted most of the regulatory risk. The prospectus also notes that, during negotiations, Boston Scientific said it was prepared to divest assets with up to $250 million of 2025 revenue if needed to win approval [1]. For investors, the gap between the target's price and the blended offer value, only about 0.2% on September 25, suggests the market expects the deal to close. Readers can compare this deal with others in DataPorium's M&A screener and track both companies on DataPorium's stock pages.
A merger announcement is only the starting point: the real value depends on how the payment is structured, which approvals remain and who bears the cost if the deal fails.
Key takeaways
- Check several premium measures: Penumbra's $374 price was a 19% premium to its 30-day average and 30% to its 90-day average.
- Read the consideration closely: a fixed exchange ratio and 73.26% cash proration cut Penumbra's blended value to about $319 when Boston Scientific stock fell.
- Track the conditions: shareholders approved in May, and an FTC Second Request extended the antitrust review.
- Note the deadlines and fees: an outside date of January 14, 2027, a $525 million break fee and a $900 million reverse fee.
Frequently asked questions
What is an acquisition premium?
An acquisition premium is the percentage by which the offer price exceeds the target's share price before the deal was announced. Boston Scientific's $374 offer for Penumbra was a 19% premium to its 30-day average price.
What does proration mean in a cash and stock merger?
Proration caps the total cash and stock paid, so holders may receive a mix even if they elect all cash or all stock. In the Penumbra deal, 73.26% of shares receive cash and 26.74% receive Boston Scientific stock.
What is a Second Request from the FTC?
A Second Request is a demand for additional information during an antitrust review under the Hart-Scott-Rodino Act. It extends the review, often by several months, but does not by itself mean the deal will be blocked.
What is a reverse termination fee?
It is a fee the buyer pays the target if the deal fails for specified reasons, often regulatory. Boston Scientific agreed to pay Penumbra $900 million if the merger is blocked or misses its outside date.
Sources & References
- [1] Boston Scientific and Penumbra proxy statement/prospectus (Form 424B3), April 1, 2026, SEC EDGAR
- [2] Boston Scientific Form 10-Q for the quarter ended June 30, 2026, SEC EDGAR
- [3] Penumbra Form 8-K: results of special meeting, May 6, 2026, SEC EDGAR
- [4] DataPorium M&A and Investment Screener (Boston Scientific and Penumbra deal record)
- [5] DataPorium Stock Market Data (PEN and BSX daily prices)
